Adenocarcinoma of the lung: lines of therapy

Cancer page →

3 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers	HER2
Early / localised	1	·
Advanced, first line	1	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Early stage	Treated as the parent's resectable and stage III pages describe; histology does not change the surgery.	Resectable stage I to III non-small-cell lung cancerUnresectable stage III non-small-cell lung cancerLobectomy		-

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Advanced, driver-negative	Pembrolizumab with platinum and pemetrexed (KEYNOTE-189), or the parent's PD-L1-high pathway when the score is 50 percent or more; datopotamab deruxtecan after chemotherapy (TROPION-Lung01).	PembrolizumabPemetrexedCarboplatinCisplatinTROPION-Lung01PD-L1-high non-small-cell lung cancer without a driver mutation		98
HER2	Advanced with a driver	Treated on the parent's driver pages (EGFR, ALK, ROS1, RET, MET, KRAS G12C, HER2, NTRK, BRAF).	Non-small-cell lung cancerEGFR-mutated non-small-cell lung cancerALK-positive non-small-cell lung cancerKRAS G12C-mutant non-small-cell lung cancerMET exon 14 and MET-amplified non-small-cell lung cancer		-

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.